natgillin/translations-raw huggingface dataset:
During in vitro studies, cloned human cardiac potassium channel (hERG), was inhibited by 15% at a concentration (30 μM) of atazanavir corresponding to 30 fold the free drug concentration at Cmax in humans. 
Tijekom ispitivanja in vitro, klonirani kalijev kanal iz ljudskog srca (hERG) bio je inhibiran za 15% kod koncentracije (30 μM) atazanavira koja je odgovarala 30 puta većoj koncentraciji slobodnog lijeka pri Cmax u ljudi.
Based on data obtained with other boosted PIs and ketoconazole, where ketoconazole AUC showed a 3-fold increase, atazanavir/ritonavir is expected to increase ketoconazole or itraconazole concentrations. 
Na temelju podataka dobivenih s drugim pojačanim inhibitorima proteaze i ketokonazola, gdje je AUC ketokonazola pokazivao trostruko povećanje, očekuje se da će atazanavir/ritonavir povećati koncentraciju ketokonazola ili itrakonazola.
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. 
Tijekom liječenja HIV infekcije moguće je povećanje tjelesne težine i povišenje razina lipida i glukoze u krvi.
Table 3. 
Tablica 3.
No recommendation regarding dose reduction can be made; therefore, caution should be exercised if atazanavir is co-administered with clarithromycin. 
Ne može se dati preporuka za sniženje doze; stoga je potreban oprez kad se atazanavir primjenjuje istovremeno s klaritromicinom.
A large prospective observational study has shown an association between an increased incidence of chronic kidney disease and cumulative exposure to atazanavir/ritonavir-containing regimen in HIV-infected patients with an initially normal eGFR. 
Veliko prospektivno opservacijsko ispitivanje pokazalo je povezanost između povećane incidencije kronične bubrežne bolesti i kumulativnog izlaganja režimu koji sadrži atazanavir/ritonavir u bolesnika zaraženih HIV-om s početno normalnim eGFR-om.
Children receiving Atazanavir Mylan may require their heart to be monitored. 
Kod djece koja uzimaju Atazanavir Mylan možda će biti potrebno pratiti rad srca.
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. 
U nekih bolesnika s uznapredovalom HIV-infekcijom (SIDA) i oportunističkom infekcijom u anamnezi mogu se pojaviti znakovi i simptomi upale od prethodnih infekcija ubrzo nakon početka anti-HIV liječenja.
Ritonavir 100 mg once daily is used as a booster of atazanavir pharmacokinetics. 
Ritonavir 100 mg jedanput na dan primjenjuje se kao pojačivač farmakokinetike atazanavira.
Caution should be used with medicinal products known to induce PR prolongations. 
Potreban je oprez s lijekovima za koje se zna da izazivaju produljenje PR intervala.
Lurasidone 
Lurasidon
Didanosine (buffered tablets) 200 mg/stavudine 40 mg, both single dose 
Didanozin (puferirane tablete) 200 mg/stavudin 40 mg, oba u jednokratnoj dozi
• carbamazepine, phenytoin, phenobarbital, lamotrigine (antiepileptics) 
• karbamazepin, fenitoin, fenobarbital, lamotrigin (antiepileptici)
Atazanavir Mylan capsules must be taken with ritonavir and have to be taken with food. 
Atazanavir Mylan kapsule moraju se uzimati s ritonavirom i treba ih uzimati s hranom.
Didanosine should be taken at the fasted state 2 hours after atazanavir taken with food. 
Didanozin treba uzeti natašte 2 sata nakon uzimanja atazanavira, koji se uzima s hranom.
The risk of a further decrease in atazanavir exposure is expected when atazanavir is given with medicinal products known to reduce its exposure (e.g., tenofovir disoproxil or H2-receptor antagonists). 
Rizik od daljnjeg smanjenja izloženosti atazanaviru očekuje se kad se atazanavir daje s lijekovima za koje se zna da smanjuju izloženost atazanaviru (npr., tenofovirdizoproksil ili antagonisti H2receptora).
Also see PULMONARY ARTERIAL HYPERTENSION in this table for further information regarding coadministration of atazanavir with sildenafil. 
Vidjeti također PLUĆNA ARTERIJSKA HIPERTENZIJA u ovoj tablici za dodatne informacije o istovremenoj primjeni atazanavira i sildenafila.
The compound selectively inhibits the virusspecific processing of viral Gag-Pol proteins in HIV- 1 infected cells, thus preventing formation of mature virions and infection of other cells. 
Taj spoj selektivno inhibira za virus specifičnu obradu virusnih proteina Gag-Pol u stanicama zaraženima virusom HIV-1 te tako sprječava stvaranje zrelih viriona i infekciju drugih stanica.
Desacetyl-diltiazem Cmin ↑121% 
Dezacetil-diltiazem Cmin ↑121%
The increased incidence of benign hepatic adenomas in female mice was likely secondary to cytotoxic liver changes manifested by single-cell necrosis and is considered to have no relevance for humans at intended therapeutic exposures. 
Povećana učestalost benignih adenoma jetre u ženki miša vjerojatno je bila posljedica citotoksičnih promjena u jetri koje su se očitovale nekrozom pojedinačnih stanica i smatra se da nema važnost za ljude pri namjeravanoj terapijskoj izloženosti.
Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3-4 fold increase in midazolam plasma levels. 
Podaci o istovremenoj primjeni parenteralnog midazolama s drugim inhibitorima proteaze ukazuju na moguće povišenje razine midazolama u plazmi za 3-4 puta.
• ketoconazole, itraconazole, and voriconazole (antifungals) 
• ketokonazol, itrakonazol i vorikonazol (antimikotici)
Stop taking Atazanavir Mylan and talk to your doctor immediately if you develop a severe rash or a rash with flu-like illness symptoms, blisters, fever, mouth sores, muscle or joint pain, swelling in the face, inflammation of the eye which causes redness (conjunctivitis), painful, warm, or red lumps (nodules). 
Odmah prestanite uzimati Atazanavir Mylan i obratite se liječniku ako se u Vas razviju teški osip ili ili osip sa simptomima bolesti nalik gripi mjehuriči, vrućica, ranice u ustima, bol u mišićima ili zglobovima, oticanje lica, upala oka koja uzrokuje crvenilo (konjunktivitis),bolni, topli ili crveni čvorići (noduli).
Immunosuppressants Cyclosporin 
Imunosupresivi Ciklosporin
Your doctor may adjust the dose of Atazanavir Mylan according to your anti-HIV therapy. 
Liječnik će možda prilagoditi dozu lijeka Atazanavir Mylan prema Vašoj anti-HIV terapiji.
Atazanavir 300 mg with ritonavir 100 mg may not provide sufficient exposure to atazanavir, especially when the activity of atazanavir or the whole regimen may be compromised due to drug resistance. 
Atazanavir od 300 mg s ritonavirom od 100 mg možda neće osigurati dovoljnu izloženost atazanaviru, osobito kad djelovanje atazanavira ili cijelog terapijskog protokola može biti promijenjeno zbog rezistencije na lijek.
Paediatric patients (at least 3 months of age and weight at least 5 kg): Other formulations of this medicine may be available for paediatric patients at least 3 months of age and weighing at least 5 kg (see relevant Summary of Product Characteristics for alternative forms). 
Pedijatrijski bolesnici (u dobi od najmanje 3 mjeseca i tjelesne težine od najmanje 5 kg): Drugi oblici ovog lijeka mogu biti dostupni za pedijatrijske bolesnike u dobi od najmanje 3 mjeseca i tjelesne težine od najmanje 5 kg (vidjeti Sažetak opisa svojstava lijeka za druge oblike).
• ciclosporin, tacrolimus, and sirolimus (medicines to decrease the effects of body's immune system) 
• ciklosporin, takrolimus i sirolimus (lijekovi za sniženje učinaka imunološkog sustava tijela)
Paediatric patients (6 years to less than 18 years of age and weighing at least 15 kg): The dose of atazanavir capsules for paediatric patients is based on body weight as shown in Table 1 and should not exceed the recommended adult dose. 
Pedijatrijski bolesnici (u dobi od 6 godina do manje od 18 godina i tjelesne težine od najmanje 15 kg) Doza atazanavir kapsula za pedijatrijske bolesnike temelji se na tjelesnoj težini, kako je prikazano u tablici 1, i ne smije biti veća od preporučene doze za odrasle.
Atazanavir binds to both alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively, at 1,000 ng/ml). 
Atazanavir se veže i za alfa-1-kiseli glikoprotein (AAG) i albumin u sličnoj mjeri (89% odnosno 86%, pri 1000 ng/ml).
ANTIEPILEPTICS Carbamazepine 
ANTIEPILEPTICI Karbamazepin
There are no dosing recommendations for Atazanavir Mylan in patients less than 3 months of age. 
Nema preporuka za doziranje lijeka Atazanavir Mylan u pedijatrijskih bolesnika mlađih od 3 mjeseca.
Do not stop taking Atazanavir Mylan before talking to your doctor. 
Nemojte prestati uzimati Atazanavir Mylan prije nego što o tome razgovarate s Vašim liječnikom
Concentrations of atazanavir (when given with ritonavir) were not significantly affected. 
Koncentracije atazanavira (kada se primjenjivao s ritonavirom) nisu bile značajno promijenjene.
During attempts to overcome the decreased exposure by increasing the dose of atazanavir or other protease inhibitors with ritonavir, a high frequency of liver reactions was seen. 
Tijekom pokušaja da se prevlada smanjena izloženost povećanjem doze lijeka atazanavir ili drugih inhibitora proteaze s ritonavirom, opažena je velika učestalost jetrenih reakcija.
Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations). 
Na temelju dostupnih viroloških i kliničkih podataka u odraslih bolesnika, ne očekuje se da će liječenje biti korisno u bolesnika zaraženih sojevima koji su rezistentni na više inhibitora proteaze (≥ 4 mutacije rezistencije na inhibitore proteaze).
Four subjects in the unboosted atazanavir group and 2 in the atazanavir + ritonavir group had HIV RNA > 500 copies/ml during the maintenance phase. 
Četiri ispitanika liječena nepojačanim atazanavirom i 2 u skupini koja je primala atazanavir + ritonavir imala su HIV RNK > 500 kopija/ml tijekom faze održavanja.
At the time voriconazole treatment is required, a patient's CYP2C19 genotype should be performed if feasible. 
U trenutku kada je potrebno liječenje vorikonazolom treba, ako je to moguće, odrediti CYP2C19 genotip bolesnika.
Atazanavir inhibits UGT and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities. 
Atazanavir inhibira UGT i može ometati metabolizam irinotekana, što rezultira pojačanim toksičnim učincima irinotekana.
Week 48: -3% [-7.6%, 1.5%] Week 96: 2.2% [-2.3%, 6.7%] HIV RNA <50 copies/ml, % by Baseline Characteristic d 
48. tjedan: -3% [-7,6%, 1,5%] 96. tjedan: 2,2% [-2,3%, 6,7%] HIV RNK <50 kopija/ml, % prema početnim značajkama d
Atazanavir was approximately 86% bound to human serum proteins over a concentration range of 100 to 10,000 ng/ml. 
Približno je 86% atazanavira bilo vezano za proteine u ljudskom serumu u rasponu koncentracija od 100 do 10 000 ng/ml.
Elevation in ALT levels were more frequently reported in paediatric patients in these studies than in adults. 
Povišenje vrijednosti ALT-a je češće prijavljeno u ovim ispitivanjima u pedijatrijskih bolesnika nego u odraslih.
Geometric mean (CV%) 
Geometrijska sredina (CV%)
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g., beclomethasone). 
Potrebno je razmotriti sniženje doze glukokortikoida uz pažljivo praćenje lokalnih i sistemskih učinaka ili prebacivanje na glukokortikoid koji nije supstrat enzima CYP3A4 (npr., beklometazon).
In healthy subjects, the renal elimination of unchanged atazanavir was approximately 7% of the administered dose. 
U zdravih je ispitanika eliminacija neizmijenjenog atazanavira putem bubrega iznosila približno 7% primijenjene doze.
The safety profile in these studies was overall comparable to that seen in previous paediatric and adult studies. 
Sigurnosni profil u tim ispitivanjima općenito je bio usporediv s onime u prijašnjim pedijatrijskim ispitivanjima i ispitivanjima u odraslih.
PDE5 inhibitors used for the treatment of erectile dysfunction: particular caution should be used when prescribing PDE5-inhibitors (sildenafil, tadalafil, or vardenafil) for the treatment of erectile dysfunction in patients receiving Atazanavir Mylan. 
Inhibitori PDE5 koji se primjenjuju za liječenje erektilne disfunkcije: potreban je poseban oprez kad se propisuju inhibitori PDE5 (sildenafil, tadalafil ili vardenafil) za liječenje erektilne disfunkcije u bolesnika koji primaju Atazanavir Mylan.
Swallow the capsules whole. 
Progutajte kapsule cijele.
Atazanavir, simultaneous administration with ddI+d4T (fasted) 
Atazanavir, istovremena primjena s ddI+d4T (natašte)
No significant effect on atazanavir concentrations was observed when administered with enteric-coated didanosine, but administration with food decreased didanosine concentrations. 
Nije opažen značajan učinak na koncentracije atazanavira kad je primijenjen sa želučanootpornim kapsulama didanozina, ali primjena s hranom smanjila je koncentracije didanozina.
Based on these data and because ritonavir is not expected to have a significant impact on the pharmacokinetics of NRTIs, the co-administration of these medicinal products and atazanavir is not expected to significantly alter the exposure of the co-administered medicinal products. 
Na temelju ovih podataka i budući da se ne očekuje značajan učinak ritonavira na farmakokinetiku NRTI-jeva, ne očekuje se da će istovremena primjena ovih lijekova i atazanavira značajno promijeniti izloženost tim istovremeno primijenjenim lijekovima.
Studies conducted in HIV-infected patients 
Ispitivanja provedena u bolesnika s HIV-infekcijom
The fluticasone propionate plasma levels increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% confidence interval 82%- 89%). 
Razine flutikazon propionata u plazmi značajno su se povisile, dok su se intrinzičke razine kortizola snizile za približno 86% (90%-tni raspon pouzdanosti: 82%-89%) Jači se učinci mogu očekivati kad se flutikazon propionat inhalira.
Studies in humans and in vitro studies using human liver microsomes have demonstrated that atazanavir is principally metabolised by CYP3A4 isozyme to oxygenated metabolites. 
Ispitivanja u ljudi i ispitivanja in vitro na mikrosomima ljudske jetre pokazala su da se atazanavir prvenstveno metabolizira putem izoenzima CYP3A4 do oksigeniranih metabolita.
The mechanism of interaction between atazanavir and tenofovir disoproxil fumarate is unknown. 
Mehanizam interakcije između atazanavira i tenofovirdizoproksilfumarata nije poznat.
Given that low dose ritonavir (100 mg twice daily) has been shown to have no significant effect on methadone concentrations, no interaction is expected if methadone is co-administered with atazanavir, based on these data. 
Budući da se pokazalo da niska doza ritonavira (100 mg dvaput na dan) nema značajan učinak na koncentraciju metadona, na temelju tih se podataka ne očekuje interakcija kod istovremene primjene metadona i atazanavira.
The resistance in antiretroviral treatment experienced patients mainly occurs by accumulation of the major and minor resistance substitutions described previously to be involved in protease inhibitor resistance. 
Rezistencija u bolesnika prethodno liječenih antiretrovirusnom terapijom uglavnom nastaje nakupljanjem glavne i sporednih supstitucija za rezistenciju, prethodno opisanih kao supstitucije koje sudjeluju u rezistenciji na inhibitor proteaze.
Cardiac monitoring is recommended based on the presence of clinical findings (e.g., bradycardia). 
Preporučuje se nadzor srčane funkcije na temelju kliničkih znakova (npr., bradikardije).
You must not take Atazanavir Mylan with certain medicines. 
Ne smijete uzimati Atazanavir Mylan s određenim lijekovima.
Mylan Hungary Kft H-2900 Komárom, Mylan utca 1 Hungary 
H-2900 Komárom, Mylan utca 1
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
Unutar svake skupine učestalosti, nuspojave su navedene od najozbiljnijih prema manje ozbiljnima.
When compared to atazanavir 300 mg with ritonavir 100 mg without tenofovir disoproxil fumarate, atazanavir concentrations are expected to be additionally decreased by about 20%. 
Kad se uspoređuje s atazanavirom 300 mg s ritonavirom 100 mg bez tenofovirdizoproksilfumarata , očekuje se da će koncentracije atazanavira biti dodatno smanjene za približno 20%.
Lipid disorders should be managed as clinicallly appropriate. 
Poremećaje lipida potrebno je prikladno klinički liječiti.
None of the de novo substitutions (see Table 4) are specific to atazanavir and may reflect re-emergence of archived resistance on atazanavir + ritonavir in Study 045 treatment-experienced population. 
Niti jedna od de novo supstitucija (vidjeti tablicu 4) nije specifična za atazanavir i može odražavati ponovnu pojavu stare rezistencije na atazanavir s ritonavirom u prethodno liječene populacije u Ispitivanju 045.
Co-administration with a high-fat meal did not affect the AUC of atazanavir relative to fasting conditions and the Cmax was within 11% of fasting values. 
Istovremena primjena s obrokom bogatim mastima nije utjecala na AUC atazanavira u odnosu na stanje natašte i Cmax je bio unutar 11% vrijednosti natašte.
Capsules should be swallowed whole. 
Kapsule treba progutati cijele.
Resistance levels to atazanavir ranged from 3.5- to 29-fold without evidence of phenotypic cross resistance to other PIs. 
Razine rezistencije na atazanavir bile su od 3,5 do 29 puta veće, bez dokaza fenotipske križne rezistencije na druge inhibitore proteaze.
The proportion of patients with HIV RNA < 400 copies/ml were 53% and 43% for ATV/RTV and 54% and 46% for LPV/RTV at weeks 48 and 96 respectively. 
Udio bolesnika s HIV RNK < 400 kopija/ml bio je 53% odnosno 43% za ATV/RTV i 54% odnosno 46% za LPV/RTV u 48. odnosno 96. tjednu.
The N88S substitution has been rarely observed in patients with virologic failure on atazanavir (with or without ritonavir). 
Supstitucija N88S rijetko je primijećena u bolesnika u kojih atazanavir (s ritonavirom ili bez njega) nije imao virološki učinak.
Do not take sildenafil with Atazanavir Mylan when sildenafil is used for the treatment of pulmonary arterial hypertension. 
Nemojte uzimati sildenafil s lijekom Atazanavir Mylan kad se sildenafil primjenjuje za liječenje plućne arterijske hipertenzije.
• sedative agents (e.g. midazolam administered by injection) 
• sedative (npr. midazolam primijenjen injekcijom)
If you develop signs or symptoms of kidney stones (pain in your side, blood in your urine, pain when you urinate), please inform your doctor immediately. 
Ako razvijete znakove ili simptome bubrežnih kamenaca (bol u slabinama, krv u mokraći, bol pri mokrenju), odmah o tome obavijestite svog liječnika.
Since atazanavir is extensively metabolised by the liver and is highly protein bound, dialysis is unlikely to be beneficial in significant removal of this medicinal product. 
Budući da se atazanavir opsežno metabolizira u jetri i vezan je za proteine plazme u visokom postotku, dijaliza najvjerojatnije neće biti korisna za uklanjanje ovog lijeka u nekoj znatnijoj mjeri.
• syncope (fainting), hypertension (high blood pressure) 
• sinkopa (nesvjestica), hipertenzija (povišeni krvni tlak)
• alopecia (unusual hair loss or thinning), pruritus (itching) 
• alopecija (neobičan gubitak ili prorijeđenost kose), pruritus (svrbež)
Efficacy data observed in the 41 paediatric patients aged 6 years to less than 18 years that received Atazanavir capsules with ritonavir are presented in Table 7. 
Podaci o djelotvornosti opaženoj u 41 pedijatrijskog bolesnika u dobi od 6 godina do manje od 18 godina koji su primali atazanavir kapsule s ritonavirom prikazani su u tablici 7.
Take Atazanavir Mylan capsules with food (a meal or a substantial snack). 
Uzimajte Atazanavir Mylan kapsule s hranom (uz obrok ili obilniji međuobrok).
5.3 Preclinical safety data 
5.3 Neklinički podaci o sigurnosti
• if you have moderate to severe liver problems. 
• ako imate umjerene do teške tegobe s jetrom.
Patients co-infected with hepatitis B and/or hepatitis C virus 
Bolesnici istovremeno zaraženi virusom hepatitisa B ili C
The effects of hepatic impairment on the pharmacokinetics of atazanavir after a 300 mg dose with ritonavir have not been studied. 
Učinci oštećenja funkcije jetre na farmakokinetiku atazanavira nakon doze od 300 mg s ritonavirom nisu ispitani.
300 mg tenofovir disoproxil fumarate is equivalent to 245 mg tenofovir disoproxil. 
300 mg tenofovirdizoproksilfumarata odgovara 245 mg tenofovirdizoproksila.
Do not use this medicine after the expiry date which is stated on the label, carton or blister. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici, kutiji ili blisteru iza kratice EXP.
Increased monitoring for rifabutinassociated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin. 
Traži se pojačan nadzor zbog nuspojava povezanih s rifabutinom, uključujući neutropeniju i uveitis, zbog očekivanog povećanja izloženosti rifabutinu.
• triazolam and oral (taken by mouth) midazolam (used to help you sleep and/or to relieve anxiety). 
• triazolam i peroralni (uzima se kroz usta) midazolam (primjenjuje se za liječenje poremećaja spavanja i/ili ublažavanje tjeskobe)
diltiazem, systemic lidocaine, verapamil) 
(amiodaron, diltiazem, sistemski lidokain, verapamil)
Atazanavir peak concentrations and AUCs were found to be approximately 26-40% higher during the postpartum period (4-12 weeks) than those observed historically in HIV infected, non-pregnant patients. 
Utvrđeno je da su vršne koncentracije i AUC atazanavira približno 26-40% više tijekom postpartalnog razdoblja (4-12 tjedana) od onih prethodno opaženih u bolesnica zaraženih HIV-om koje nisu bile trudne.
The mean half-life of atazanavir in hepatically impaired subjects was 12.1 hours compared to 6.4 hours in healthy subjects. 
Srednja vrijednost poluvijeka atazanavira u ispitanika s oštećenjem funkcije jetre iznosila je 12,1 sat, dok je u zdravih ispitanika iznosila 6,4 sata.
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long- term exposure to combination antiretroviral therapy (CART). 
Zabilježeni su slučajevi osteonekroze, osobito u bolesnika s općenito poznatim čimbenicima rizika, uznapredovalom HIV-bolešću ili dugotrajnom izloženošću kombiniranoj antiretrovirusnoj terapiji.
If atazanavir is co-administered with irinotecan, patients should be closely monitored for adverse events related to irinotecan. 
Ako se atazanavir primjenjuje istovremeno s irinotekanom, bolesnike treba pažljivo pratiti zbog nuspojava povezanih s irinotekanom.
Increased clinical and laboratory monitoring for HIV suppression is warranted. 
Obavezan je pojačan klinički i laboratorijski nadzor supresije HIV-a.
Metabolic parameters Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4). 
Tjelesna težina i razine lipida i glukoze u krvi mogu biti povećane tijekom antiretrovirusne terapije (vidjeti dio 4.4.).
Consult the dosing table for the specific formulation (see relevant Summary of Product Characteristics). 
Provjerite tablicu doziranja za određeni oblik (vidjeti Sažetak opisa svojstava lijeka za druge oblike).
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). 
Iako se smatra da postoji više uzroka osteonekroze (uključujući primjenu kortikosteroida, konzumaciju alkohola, tešku imunosupresiju, povišen indeks tjelesne mase), slučajevi osteonekroze zabilježeni su osobito u bolesnika s uznapredovalom HIV-bolešću i/ili dugotrajnom izloženošću kombiniranoj antiretrovirusnoj terapiji.
Talk to your doctor immediately if you get dizzy, lightheaded or if you suddenly faint. 
Obratite se odmah liječniku osjećate omaglicu, ošamućenost ili se iznenada onesvijestite.
Includes patients with baseline resistance data. 
Uključuje bolesnike s početnim podacima o rezistenciji.